Synapticure

November is National Family Caregivers Month—a time to shine a light on the compassion and commitment of those who care for others, often without recognition. This month, we’re excited to celebrate one of our own: Synapticure Care Navigator, Sabrina Johnson, whose dedication makes a profound difference every day. As a family caregiver herself, Sabrina is all too familiar with the challenges caregivers face. She knows what it's like to navigate the questions, the exhaustion, and the search for hope. In a recent blog post, she breaks down Emma Heming Willis' The Unexpected Journey, and how it guides caregivers as they learn to balance self-care, with their loved one's diagnosis. 💙 Find a copy at: https://vist.ly/4fz74 Read Sabrina’s full post: https://lnkd.in/dbYRsWDu

We're hiring a Partner Success leader to be the face of Synapticure with our healthcare partners – bringing innovative programs to life and expanding access to neurodegenerative care. If you love solving hard problems and building lasting partnerships, we'd love to meet you. Apply here: https://lnkd.in/egcfZG5K

Synapticure is excited to share that we will be hosting a webinar on October 28, 2025 with participants in the Neuralink ongoing ALS trial, along with representatives from the company. The webinar will feature Brad Smith, Jake Schneider, and Nick Wray—three individuals with ALS participating in Neuralink’s clinical trials to explore the use of BCI technology in their daily lives. In the webinar we will discuss the technology, the decisions patients make to participate in studies around BCI technology, and connect with patients who have enrolled in the study and are using Neuralink today.  To register for the webinar link below. We hope to see you on the 28th! Register here to attend, ask questions and / or receive the recording. #ALS #BCI https://lnkd.in/gbk-rhfu

Synapticure’s Clinical Research team, led by Abigail O'Connell and Eric Anderson MD PhD MBA FAAN, is excited to join the NEALS Annual Conference next week in Clearwater, Florida October 7-10th! We’re looking forward to connecting with colleagues and collaborators to discuss how Synapticure is expanding remote access to research participation for people living with ALS—helping patients enroll and stay engaged in trials regardless of where they live. We’ll also be presenting a poster with our colleagues at Clene Nanomedicine and Jinsy Andrews: “A Comparison of Baseline Clinical Characteristics Between Decentralized and Institutionally-Enrolled Participants in the CNM-Au8 EAP04 Study” If you’ll be at NEALS, we’d love to connect—whether to discuss partnerships, share insights, or explore how we can work together to bring more inclusive research opportunities to ALS patients everywhere. Reach out to partners@synapticure.com for more information or to schedule a meeting #NEALS #NEALS2025 #ALS #clinicalresearch #DCT #hybridtrials

We’re proud to share that Synapticure’s R&D lab contributed to a new study from Dr. Sami Barmada’s group at the University of Michigan, published in the Journal of Clinical Investigation. This important work uncovers how a disrupted protein, Nemo-like kinase (NLK), leads to a central hallmark of ALS biology. We are excited to have played a part in this paper. Using our granulin-deficient 3D cortical brain spheroids, a system with these central hallmarks of ALS and FTD biology, Synapticure validated that this protein is elevated consistent with what’s observed in patient tissue. This study highlights the power of our patient-derived brain model platform to: - Recapitulate human disease biology - Validate therapeutic targets emerging from discovery pipelines - Provide a translational bridge between patient data and preclinical development Congratulations to Dr. Barmada, Michael Bekier, Emile Pinarbasi, and all of the authors on this important advance. We’re excited to see our models helping accelerate insights that move the field closer to effective therapies for ALS and related neurodegenerative diseases.

We’re thrilled to share that our CEO & Co-Founder, Sandra Abrevaya, will be a featured keynote speaker at the New York Brain-Computer Interface Symposium (#NYBCI25) on October 3-4 in New York City! Sandra will present “The Power of Advocacy: Driving BCI Forward,” highlighting how patient voices and advocacy guide research, shape policy, and keep people at the center of innovation. We’re honored to be part of this global conversation and can’t wait to share what’s ahead in #neurotech.